IMDX vs VTR · rev $271.0K vs P/E 149, rev $1.73B
Insight Molecular Diagnostics Inc. (IMDX) versus Ventas Inc (VTR) — a side-by-side from cached financials, not a winner call.
Insight Molecular Diagnostics Inc. (IMDX) is a diagnostics & research company listed on US.
Ventas Inc (VTR) is a reit - healthcare facilities company listed on NYSE.
Latest reported IMDX revenue for 2026-06-30 was $271.0K. Net income was -$15.6M. IMDX currently screens at market cap $0.
Latest reported VTR revenue for 2026-06-30 was $1.73B. Net income was $72.2M. Revenue was up 4.4% from 2026-03-31 to 2026-06-30. VTR currently screens at market cap $39.94B and trailing P/E 149.4.
IMDX currently screens at market cap $0. VTR currently screens at market cap $39.94B and trailing P/E 149.4.
Not investment advice. Open the IMDX and VTR stock pages for the full models.
Not investment advice.